Halozyme Therapeutics Aktie
58,66
EUR
+0,02
EUR
+0,03
%
69,54
USD
-0,01
USD
-0,01
%
Werbung
Halozyme Therapeutics Aktie Analyse
| 15.11.24 | Halozyme Therapeutics Neutral | JP Morgan Chase & Co. | |
| 27.09.12 | Halozyme Therapeutics neutral | UBS AG | |
| 12.08.08 | Halozyme Therapeutics hold | Brean Murray, Carret & Co., LLC |
Werbung
Werbung